Healthcare

This research service encompasses microbiome technology trends and emerging innovations across: Disease Management This research segment explores the emerging role of microbiome-based therapeutics across a wide range of diseases, especially in the context of gastro-intestinal health, while providing strategic insights across the highly dynamic com...

The impressive advances in life sciences research and development (R&D) befallen in the past two-three years are playing a leading role in the transformation of the healthcare industry. A myriad of new developments in the fields of gene and cell therapies, empowered with nanotechnology advances, omics technologies and novel smart molecules approach...

The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme repl...

Recent advancement in the development of novel platforms of smart targeting small molecules, gene therapy, stem cell therapy, gene modification, and gene rectification technologies pose new prospects for therapies and cures for rare and genetic diseases. More than 80% of rare diseases are genetic in origin, so that gene and cell therapies are being...

In an increasingly convergent industry such as healthcare, business collaborations are not only a necessity, but an inevitability. It is interesting to note that technologies and market segments that receive the most funding and research focus, are also the areas that are ripe for collaborative partnerships. Market segments such as personalized med...

The research service aims to give a global outlook of the companion diagnostic market landscape, with a specific focus on Western European countries. The segments related to oncology discussed in this study include breast cancer, lung cancer, colorectal cancer and other cancers, and non-oncology related infectious disease, CNS, and cardiovascular. ...

Monoclonal antibody therapeutics are being used for treatment of a wide array of diseases, specially in therapeutic areas such as oncology, immunology (including autoimmune and inflammatory diseases, as well as, transplant rejection) and neuroscience. The development of these new molecular agents, successfully directed to specific cellular targets,...

This research service focuses on the current status of candidates for opioid therapeutics with a focus on current Phase 3 candidates, detailed timelines, rational for pivotal program design, Phase 2 data review and key opinion leader (KOL) commentary. A pipeline assessment is provided for all active candidates in development. The information contai...

With the growing need for better therapeutics, and the current patent cliff that is underway, therapies such as monoclonal antibodies, recombinant protein therapeutics and even vaccines for a whole host of indications are in high demand. Conventionally expression systems were utilized to aid in the development and production of these therapeutics...